Adicet Bio, Inc.

Adicet is a clinical stage biotechnology company discovering and developing a leading-edge type of treatment called a cell therapy.

Cell therapy involves the transfer of intact, live bioengineered cells into a patient to treat or cure a disease. The cells may originate from the patient (autologous) or from a donor (allogeneic).

Adicet selected the gamma delta 1 T cell because it:

  • May provide B-cell depletion leading to immune reset for patients with autoimmune diseases.
  • Has multiple ways to target and kill cancer cells and facilitate innate and adaptive immune responses in cancer.

We also chose to use cells from donors (allogeneic) to enable our potential therapies to be readily available when needed (taken “off-the-shelf” or available to the patient on demand).

For more information, please visit our website at http://www.adicetbio.com.

1000 Bridge Parkway Redwood City California 94065 US
  • Featured Employer
  • NextGen Class of 2017
OUR MISSION & VALUES

Adicet was founded on innovation and a deep passion for translating cutting edge science into treatments for patients. This spirit is the cornerstone of our values today and we are proud to attract and retain some of the greatest talent in the biopharma and cell therapy space.

Our team thrives on working together to live our MISSION to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases and cancer. Together, we Collaborate to Innovate Courageously to develop new therapies that have curative potential for patients. We Empower our teams to exercise Excellence while Appreciating each other as we Develop our teams and these new therapies for patients.

BENEFITS

At Adicet, our people are an important focus. We believe that attracting and retaining the best and brightest is the key to achieving our mission to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases and cancer.

Our people – their health, happiness and growth opportunities – matter

We offer generous financial incentives, including: competitive compensation package including base salary, annual cash bonuses, and long-term incentives (stock options); an Employee Stock Purchase Plan (ESPP) and a 401(k) with ROTH and a 4.5% Company match.

To ensure the wellness and protection of you and your loved ones, we offer:
Comprehensive health plans (medical, dental, vision, etc.); Flexible Health and Commuter Spending Accounts (FSA) and company matched Health Savings Account (HSA). We also offer a life, AD&D, short- and long-term disability insurance and legal, pet and various other voluntary insurance programs.

We also believe our greatest ideas come when we are refreshed and focused, and we offer: generous paid time-off including 17 company holidays with end-of-year shutdown, vacation, sick time; and paid parental leave.

With “Develop” as one of our Values, we also offer an Educational Reimbursement program which is a benefit that allows employees to develop new skills or enrich the ones they currently possess. Employees can receive reimbursement on a pre-tax basis up to $4k per calendar year. This is in addition to an expertly curated curriculum we offer through LinkedIn Learning.

Adicet is located in a state-of-the-art facility and works to create an incredible office experience with: free onsite gym and various other fitness options; abundant, zero-cost, onsite parking with electric vehicle charging stations and free shuttle (Caltrain); lunches (delivered onsite) and fully stocked breakrooms.

  • ADICET 1.jfif
  • ADICET 2.jfif
  • ADICET 3.jfif
  • ADICET 4.jfif
NEWS
Looking for a quality control job? Check out these nine companies hiring life sciences professionals like you.
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO.
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Genentech announced new data related to its investigational CD20xCD3 T-cell engaging bispecific antibody intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Innocoll Biotherapeutics, Genapsys, and Adicet Bio announced today their relocation and expansion plans.
ADI-001 generated positive early responses from three of four evaluable participants, two of whom achieved complete responses while one had a partial response that researchers logged as “near complete.”
Adicet Bio announced pricing of an underwritten public offering of 9,230,770 shares of its common stock, marking it at a public offering per-share price of $13.00.
JOBS
IN THE PRESS